A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

The rise of misinformation online has helped fringe health ideas go mainstream and eased RFK Jr.'s path to confirmation as ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Salk immunologists discover Prozac, an SSRI and one of the most prescribed drugs, protects against sepsis, wherein the body's ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Nine of 24 people with measles in Texas are hospitalized for a disease that was considered eliminated in 2000. Kennedy has ...